Preparation and Characterization of Fluconazole-loaded Gelatin Fiber Scaffolds for Inhibiting Candida Albicans.

doi:10.13701/j.cnki.kqyxyj.2018.04.023

Abstract

Abstract: Objective: To develop fluconazole-loaded gelatin fiber scaffolds for inhibiting the growth of candida albicans, and to explore their physicochemical properties and biological properties. Methods: The fluconazole-loaded gelatin fiber scaffolds were prepared by electrospinning, and the morphology was observed by SEM. The amount of fluconazole release was detected by UV spectrophotometry. The adhesion property was observed by cell adhesion assay and the biosafety was detected by MTT. Candida albicans were cultured in vitro to test its inhibitory effect on candida albicans. Results: The fluconazole-loaded gelatin fiber scaffolds exhibited nanoscale diameter with interlaced three-dimensional network structures, and the degradation rate in vitro was about 10% after 5 days. The cell viability was high. Some cells adhered to the surface of scaffolds, and the others extended into it. Fluconazole released fast within the first 6 hours, then got slow. Scaffolds had inhibitory effect on candida albicans. Conclusion: Fluconazole-loaded gelatin fiber scaffolds have good stability, adhesion, and biosafety with large and lasted drug release ability. The inhibitory effect on candida albicans is excellent.

Key words: Gelatin fiber scaffolds, Fluconazole, Candida albicans

ZHOU Yang, LI Chen, GAO Xu, MA Xiao-zhou, LIU Chang, XUE Xiao-han, WEI Xiu-feng. Preparation and Characterization of Fluconazole-loaded Gelatin Fiber Scaffolds for Inhibiting Candida Albicans.[J]. Journal of Oral Science Research, 2018, 34(4): 437-441.

References

[1] Ohshima T, Kojima Y, Seneviratne CJ, et al. Therapeutic application of synbiotics, a fusion of probiotics and prebiotics, and biogenics as a new concept for oral candida infections: a mini review [J]. Front Microbiol, 2016, 7∶10
[2] Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America [J]. Clin Infect Dis, 2016, 62(4)∶e1-e50
[3] Yehia SA, El-Gazayerly ON, Basalious EB. Design and in vitro/in vivo evaluation of novel mucoadhesive buccal discs of an antifungal drug: relationship between swelling, erosion, and drug release [J]. AAPS Pharm SciTech, 2008, 9(4)∶1207-1217
[4] Zafar M, Najeeb S, Khurshid Z, et al. Potential of electrospun nanofibers for biomedical and dental applications [J]. Materials (Basel), 2016, 9(2). pii: E73
[5] 陈谦明.口腔黏膜病学[M].第4版.北京:人民卫生出版社,2012∶34-42
[6] Berkow EL, Lockhart SR. Fluconazole resistance in Candida species: a current perspective [J]. Infect Drug Resist, 2017, 10∶237-245
[7] Akbar E, Syed NM. Synthesis of a novel structure for the oral delivery of insulin and the study of its effect on diabetic rat [J]. Life Sci, 2017, 186∶43-49
[8] Tamás V, Tímea H, Attila B, et al. Polymer-free and polyvinylpirrolidone-based electrospun solid dosage forms for drug dissolution enhancement[J]. Eur J Pharm Sci, 2013, 49(4)∶595-602
[9] Ainola M, Tomaszewski W, Ostrowska B, et al. A bioactive hybrid three-dimensional tissue-engineering construct for cartilage repair [J]. J Biomater Appl, 2016, 30(6)∶873-885
[10] 张震,李莹,耿亚伟,等.纳米支架及合成技术在神经组织再生的应用[J].口腔医学研究,2017,33(4)∶459-462
[11] Ranjbar-Mohammadi M, Zamani M, Prabhakaran M, et al. Electrospinning of PLGA/gum tragacanth nanofibers containing tetracycline hydrochloride for periodontal regeneration [J]. Mater Sci Eng C Mater Biol Appl, 2016, 58∶521-531
[12] Pawar S, Pande V. Oleic acid coated gelatin nanoparticles impregnated gel for sustained delivery of zaltoprofen: formulation and textural characterization [J]. Adv Pharm Bull, 2015, 5(4)∶537-548
[13] Huang CY, Hu KH, Wei ZH. Comparison of cell behavior on pva/pva-gelatin electrospun nanofibers with random and aligned configuration [J]. Sci Rep, 2016, 6∶37960
[14] Ji W, Sun Y, Yang F, et al. Bioactive electrospun scaffolds delivering growth factors and genes for tissue engineering applications [J]. Pharm Res, 2011, 28(6)∶1259-1272
[15] Khanvilkar K, Donovan MD, Flanagan DR. Drug transfer through mucus [J]. Adv Drug Deliv Rev, 2001, 48(2-3)∶173-193